Analyst ahead of ALK report: Focus will be on 2022 prognosis

Allergy company ALK will showcase relatively high R&D costs and will likely also report of increasing marketing expenses in tomorrow’s financial report, says an analyst from Sydbank.
Photo: ALK / PR
Photo: ALK / PR
by marketwire, translated by daniel pedersen

Sales growth of ALK’s allergy tablets alongside the 2022 guidance will be center stage tomorrow, when the allergy company publicizes its full-year financial report.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading